The presence of PK-res αSyn aggregates in the SN of Thy1-αSyn mice is a key distinguishing characteristic of brain tissue in this model and, more importantly, in human PD with Lewy bodies [48, 49]; thus any effects of DDL-112 treatment on the levels of these aggregates [50] mediated by EV-mediated proteoapathic spread [51] was the focus of our IHC analyses. This evidence concerns the gene THY1 and Parkinson disease.